Meridia labeling
Executive Summary
Abbott met with FDA Chief Counsel Daniel Troy July 11 to discuss labeling issues for Meridia (sibutramine). Public Citizen's petition requesting withdrawal of the obesity agent has been pending at FDA since March 2002 (1"The Pink Sheet" March 25, 2002, p. 21)...
You may also be interested in...
Public Citizen continues to press Meridia withdrawal
Public Citizen submits second petition calling for FDA to ban Abbott's diet drug Meridia (sibutramine). The first petition, submitted March 19, 2002, cited 19 deaths from cardiovascular disease from February 1998 to September 2001. The 1second petition, submitted Sept. 3, includes 30 additional reports of cardiovascular deaths in Meridia patients. Abbott met with FDA Chief Counsel Dan Troy June 11 to discuss Meridia labeling (2"The Pink Sheet" July 21, 2003, In Brief)...
Meridia Fatality Rate “Substantially Lower” Than Obese Population – Abbott
Abbott's Meridia patient fatality rate is "substantially lower" than what would generally be expected from the obese population, the company maintains in response to a Public Citizen Health Research Group petition calling for the drug's withdrawal
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.